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Somsak Tiamkao1,2*, Kittisak Sawanyawisuth1 and Alongkorn Chancharoen1Abstract
Background: Status epilepticus (SE) is a serious neurological condition and requires prompt treatment. Sodium
valproate has been used to treat SE successfully but its role as the first-line antiepileptic drug (AED) is still
controversial. This study evaluated the efficacy of intravenous sodium valproate to determine if it is non-inferior to
intravenous phenytoin in SE treatment.
Methods: Patients diagnosed as SE during 2003–2010 who were of an age of more than 15 years and received
either intravenous sodium valproate or intravenous phenytoin as the first-line treatment were enrolled. Clinical
characteristics and outcomes of SE were recorded and analyzed. The differences of outcomes between sodium
valproate and phenytoin group were determined by descriptive statistics.
Results: During the study period, there were 37 and 17 SE patients who received intravenous phenytoin and
intravenous sodium valproate as the first-line treatment, respectively. All patients received diazepam 10 mg
intravenously as a rescue medication before starting the antiepileptic agents if uncontrolled except one patient in
the sodium valproate group. There were no significant differences between the phenytoin and sodium valproate
groups in all outcome variables including numbers of patients with clinically-controlled seizures, non-dependent
patients, time to seizure control, and duration of hospitalization, and death. No serious cardiovasculars event such
as hypotension occurred in either group.
Conclusion: Intravenous sodium valproate is non-inferior to intravenous phenytoin as the first-line treatment in SE
with no significant cardiovascular compromises.
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Status epilepticus (SE) is an emergency condition that
requires proper and prompt treatment to prevent morbid-
ity and mortality. Intravenous phenytoin is a main medica-
tion to treat SE. Recent and new antiepileptic drugs (AED)
such as sodium valproate, lacosamide, levetiracetam or
topiramate have potential benefits in treatment of SE [1-4].
Previous studies showed that intravenous sodium val-
proate may be a potential AED to be effective in SE [1,5].
It may be used as the first-line AED in SE with a good
seizure control [5]. Unlike phenytoin [6-8], sodium* Correspondence: somtia@kku.ac.th
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reproduction in any medium, provided the orvalproate can be used safely and has no potential major
cardiovascular compromises such as cardiac arrhythmia
or hypotension [9-12]. Sodium valproate therefore may
be an appropriate drug as the first-line treatment in SE.
A meta-analysis of five randomized-controlled studies
showed that both intravenous phenytoin and sodium val-
proate were effective in SE treatment [1]. This study aims
to investigate the efficacy of both medications in the
treatment of SE as the first-line AED. The results will
add more information of the efficacy of both drugs on SE
in the literature. The study therefore evaluated if intraven-
ous sodium valproate is non-inferior to intravenous pheny-
toin in SE treatment.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SE patients treated at Srinagarind Hospital, Khon Kaen
University, Thailand between 2003 and 2010 were enrolled.
The inclusion criteria were patients with an age of more
than 15 years and received either intravenous phenytoin
or intravenous sodium valproate as the first-line treatment.
Status epilepticus (SE) is a condition with persistent
seizure more than 5 minutes or the patient does not gain
the consciousness during the interictal period [13]. Gen-
eralized convulsive SE is defined as recurrent convulsive
seizures that may be overt or subtle, symmetric or asym-
metric, and are associated with profound coma and bi-
lateral, although often has asymmetric, ictal discharges
on electroencephalogram (EEG) [14]. Non-convulsive SE
is defined as SE with a change in behavior and/or mental
processes from baseline associated or associated with
continuous epileptiform discharges in the EEG or in re-
sponse to treatment [15].
Data were retrieved from medical records including
baseline characteristics, previous medical illnesses, causes
of SE, laboratory findings, numbers of AED usage, and
outcomes of treatment. The outcomes of treatment were
numbers of patients with clinically-controlled seizure, timeTable 1 Baseline characteristics of status epilepticus (SE) pati
sodium valproate as the first-line treatment
Variables Phenytoin group N
Age;(years) 40 (16–85)
Male gender (%) 17 (45.95)
No preexisting condition, N (%) 5 (13.51)
History of epilepsy (%) 6 (16.22)
Antiepileptic drug withdrawal (%) 4 (10.81)
Admitted to internal medicine ward (%) 14 (37.84)
Generalized tonic clonic seizure type (%) 37 (100)
Weight (kgs)* 55.5 (40–75)
Time to start treatment (minutes) 5 (5–90)
Independent status prior to SE, N (%) 28 (75.68)
Laboratory findings
Hematocrit, g/dL* 31 (15.6-45.7)
Total white blood cells, cells/mm3* 11610 (4100–29700)
Blood sugar, mg/dL* 127 (37–568)
Serum creatinine, md/dL* 1 (0.5-6.1)
Serum calcium, md/dL* 8.4 (5.3-10.2)
Serum albumin, g/dL* 3.3 (1.2-7.4)
ALT, U/L* 30 (5–375)
AST, U/L* 56 (11–473)
Creatinine kinase, U/L* 276 (54–1500)
Abnormal CT brain findings* 17 (58.62)
Electroencephalogram, N* 9 (24.32)
Note. Data presented as median (range) or number (percentage), Data in phenytoin
missing data, ALT serum alanine transaminase, AST serum aspartate transaminase, Cto seizure control, admission duration, patient status after
treatment, change of functional status after treatment, and
death. Time to seizure control was identified by the total
minutes spent from the start of SE treatment to the time
until there was no clinical evidence of seizure. Seizure
control was defined clinically and/or by EEG. Patient
status after treatment was defined by patient’s func-
tional capacity at the discharge date from the hospital
and categorized as dependent or non-dependent status.
The dependent status was defined as a condition that
the patients needed someone to assist them daily life ac-
tivities and equal to modified Rankin scale (mRs) of two
or more. Worsening of functional outcome was defined
by change of functional outcome to dependent status
or death at discharge date. Mortality rate and duration
of treatment were recorded.
Baseline characteristics between phenytoin and sodium
valproate group were compared by descriptive statistics.
All outcome variables were also tested for the differ-
ences between those treated with phenytoin and sodium
valproate. Wilcoxon rank sum or student t-test and Fisher’s
exact tests or Chi-square test were applied to compare
the differences in numbers and proportions between theents treated with intravenous phenytoin or intravenous






















or sodium valproate group may not equal to 37 or 17, respectively due to
T computed tomography, * indicates missing data.
Table 2 Causes of status epilepticus (SE) patients treated with intravenous phenytoin or intravenous sodium valproate
as the first-line treatment
Causes Phenytoin group N = 37 Sodium valproate N = 17 p value
Antiepileptic drug withdrawal 4 (10.81) 5 (29.41) 0.121
Sepsis 7 (18.92) 0 0.084
Uremia 0 1 (5.88) 0.315
Cardiac arrest 5 (13.51) 2 (11.76) 1.000
Alcohol withdrawal 1 (2.70) 0 1.000
CNS infection 9 (24.32) 3 (17.65) 0.584
Head injury 2 (5.41) 0 1.000
Metabolic causes 9 (24.32) 1 (5.88) 0.105
Others* 10 (27.03) 6 (35.29) 0.537
Note. Data presented as median (range) or number (percentage); *phenytoin group: hypoxic encephalopathy 3, CNS vasculitis 2, epidural hematoma 1,
postcraniotomy 1, tuberculous encephalitis 1, venous thrombosis 1, ischemic stroke 1; sodium valproate group: postcraniotomy 2, saggital sinus thrombosis 1,
subarachnoid hemorrhage 1, intracerebral hemorrhage 1, pregnancy with eclampsia.
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approved by the ethics committee on human research of
Khon Kaen University (HE541319).
Results
During the study period, there were 92 patients diagnosed
as SE. Of those 37, 17 SE patients received intravenous
phenytoin and 20 received intravenous sodium valproate
as the first-line treatment. All patients received diazepam
10 mg intravenously as a rescue medication before starting
antiepileptic agents if uncontrolled except one patient in
the sodium valproate group.
There were no statistically significant differences in the
baseline clinical variables between both groups (Table 1).
The median age was higher and the median time to start
SE treatment was longer in sodium valproate group. The
percentages of patients with male gender, epilepsy, and
antiepileptic drug withdrawal were also higher in sodium
valproate group. EEG was done in 14 patients (25.93%).
There were no statistically significant differences, however,
in terms of causes and pre-existing conditions of SE in
both groups (Table 2). Details of history of AED usage inTable 3 Antiepileptic drug usage in status epilepticus
treated by intravenous phenytoin and intravenous
sodium valproate as the first-line treatment
Phenytoin group Sodium valproate group
1. Phenytoin 1. Sodium valproate
2. Phenytoin, Phenobarbital 2. Sodium valproate
3. Phenytoin, Phenobarbital 3. Phenytoin, Phenobarbital
4. Phenytoin 4. Sodium valproate, Phenobarbital
5. Phenytoin, Phenobarbital 5. Sodium valproate, Phenytoin
6. Phenytoin, Sodium valproate 6. Topiramate
7. Topiramate
Note. Bold letter indicates status epilepticus from antiepileptic
drug withdrawal.patients with previous history of epilepsy are provided
in Table 3.
The mean doses of AED used in phenytoin and sodium
valproate group were 1.95 (SD 0.85) and 1.82 (SD1.01),
(p value 0.508). The numbers of patients with two or
more AED usage were 10 (27.02%) and 5 (29.41%) in
the phenytoin and sodium valproate groups, respect-
ively (Table 4). Details of AED order of usage in each
group are shown in Table 5. The average loading dose
of phenytoin was 743 (SD 116) mg with the infusion
rate of 20.63 (SD 9.54) mg/min, while sodium valpro-
ate was given intravenously at average loading dose
of 1000 (SD 239.14) mg and an infusion rate of 26.27
(SD 10.76) mg/min. Then, both medications were given
intravenously with maintenance doses of 300 mg of
phenytoin and 1,200 mg of sodium valproate. The serum
phenytoin levels were measured in 16 patients. The
average phenytoin level was 25.71 (SD 28.65) mg/dL,
while the average sodium valproate level was 36.82
(SD 73.45) mg/dL (calculated from 7 patients).
Regarding the treatment outcomes (Table 6), there
was no significant difference between the phenytoin and
sodium valproate groups in all outcome variables. The
differences of numbers of clinically-controlled seizure,
however, was almost reached a statistical significant level
(p value = 0.057). The time to seizure control, durationTable 4 Numbers of antiepileptic drug (AED) used in
status epilepticus patients by group




1 13 (35.14) 9 (52.94)
2 14 (37.84) 3 (17.65)
3 9 (24.32) 4 (23.53)
4 1 (2.70) 1 (5.88)








Rescuer Diazepam 37 Diazepam 16
First-line Phenytoin 37 Sodium valproate 17
Second- line Phenytoin 9 Sodium valproate 7
Phenobarbital 8 Phenytoin 1
Sodium valproate 7




Fourth- line Phenobarbital 1 Sodium thiopenthal 1
Note. Numbers after each antiepileptic drug indicates number of patients.
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tients or death were better in sodium valproate group
(p value > 0.05) as shown in Table 6. There were 13
patients who died during the admission; 2 patients in
the sodium valproate group. The median hospitalization
days of all 13 patients were 9 days (range 3–31 days). Two
patients died from acute renal failure and rhabdomyolysis,
while the others died from septicemia. No serious car-
diovascular eventd such as hypotension occurred in
either group.Discussion
This study showed that intravenous sodium valproate
has non-inferior efficacy to intravenous phenytoin as the
first-line treatment of SE. The intravenous sodium val-
proate group had better outcomes in all five variables
(Table 6). Numbers of patients with clinically-controlled
seizures was almost statistically significant (p value 0.057).
A previous study by the present authors [5] showed that
intravenous sodium valproate can control SE better if
used as the first-line compared to the second-line treat-
ment (75% vs 35%). Even though some causes or pre-
existing conditions such as AED withdrawal induced SE
may be easier to control [16], there was no statisticalTable 6 Six outcome variables of status epilepticus patients t
the first-line treatment
Outcomes Phenytoin N = 37
Seizure controlled, N 8 (21.62)
Time to seizure controlled (minutes) 30 (20–30)
Hospitalization (days) 12 (3–109)
Non-dependent status, N 20 (54.05)
Worsening functional status, N 20 (54.05)
Death, N 11 (29.73)
Note. Data presented as median (range) or number (percentage); p value was calcusignificance between the groups regarding these two
factors (Tables 2 and 3).
The most different outcome between intravenous sodium
valproate and phenytoin is the number of non-dependent
status patients (22.42%). At baseline, patients in sodium
valproate group were all independent, while 75.68% in
phenytoin group were independent (p value 0.77). After
having SE, the functional status at discharge of both
groups were decreased (23.53% in sodium valproate group
and 21.63% in phenytoin group, p value 0.143). The
baseline functional status of patients in sodium valproate
group was better phenytoin group (Table 1) but numbers
of patients with worsening functional status (Table 6)
was higher in phenytoin group (54.05% vs 41.18%,
p value 0.559). The results of the number of patients
with worsening of functional status at discharge sug-
gested that patients in the sodium valproate group may
have better functional outcomes at discharge.
None of the patients died during the seizure attack but
the median survival was 9 days. Two patients died from
SE related complications or rhabdomyolysis. Both patients
were treated with phenytoin. The mortality rate in the
sodium valproate group was much lower than phenytoin
group (11.76% vs 29.73%; p value 0.189). Note that small
numbers of patients in sodium valproate group. A fur-
ther prospective study is therefore needed to confirm
this finding. The non-significant results of all six out-
comes are suggesting that sodium valproate was not
inferior to phenytoin as the first-line treatment in SE as
previously shown by the meta-analysis [1]. These findings
are also compatible with a study from Iran with 30 SE
patients. Both medications had comparable efficacy but
phenytoin caused more non-serious or skin reactions at
the injection site (26.7% vs 0%, p value 0.03) [17].
The reason that intravenous sodium valproate was used
commonly in the KKU Hospital during the study period is
due to a lack of intravenous phenobarbital. There were
no serious cardiovascular compromises in patients who
received intravenous sodium valproate. This indicated
that intravenous sodium valproate is safe and effective
to use as the first-line treatment in SE. Previous studies
also showed comparable efficacy of intravenous sodiumreated by intravenous phenytoin or sodium valproate as







lated by *Chi-square, **Fisher Exact test, or ***Wilcoxon rank sum test.
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toin [1,17].
There are some limitations to the present study. The
retrospective study design had incomplete data collec-
tion. The numbers of patients in each group were also
not comparable. Phynytoin is recommended as the first-
line antiepileptic drug for status epilepticus in Thailand,
while sodium valproate may be used in the elderly, patients
with cardiovascular risks or hepatitis. Physicians therefore
may choose phenytoin more often than sodium valproate.
The outcomes, however, were better in the sodium valpro-
ate group. The other limitation is small number of patients
in each group. In addition, a prospective study comparing
intravenous phenytoin and intravenous sodium valpro-
ate as the first-line treatment in SE patients is needed
to confirm that intravenous sodium valproate can be
used as the first-line AED for recommendations in the
SE guidelines.
Conclusion
Intravenous sodium valproate is non-inferior to intraven-
ous phenytoin as the first-line treatment in SE with no
significant cardiovascular compromises.
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